Business Wire

AZ-BLUE-YONDER

20.6.2024 10:01:28 CEST | Business Wire | Press release

Share
Waitrose Invests in Blue Yonder’s Industry Leading Demand Forecasting Capability to Further Improve Customer Satisfaction

Waitrose is extending its collaboration with Blue Yonder with the addition of the supply chain solution provider’s industry-leading forecasting capability.

The new move will mark the first significant introduction of artificial intelligence (AI) into Waitrose’s forecasting – and is designed to improve the already high levels of availability across the retailer’s stores.

Rather than relying on historical sales data and human intuition, the AI forecasting capability – part of Blue Yonder Demand Planning – focuses on customer behaviour and analyses ‘why’ customers bought what they did rather than just ‘what’ they bought.

The capability understands and learns from the trading environment to provide a better forecast based on customer behaviour. For example, it will learn how customers responded to a variety of influences, including weather variations, major sporting and cultural events, and promotions.

The upgrade is part of a significant investment in technology across Waitrose’s supply chain and is designed to improve availability, which already stands at record levels.

It is also expected to:

  • Improve customer satisfaction score by increasing on-shelf availability and refocusing store Partners from manual ordering to more strategic customer-oriented tasks.
  • Leverage AI capabilities to ingest and analyse massive volumes of data without overwhelming users.
  • Assess risks by weighing different forecasting outcomes.
  • Determine stock volumes dynamically to minimise waste.
  • Respond to demand fluctuations automatically, quickly and accurately.

Alison Maffin, Waitrose Supply Chain Director, said: “Whether we are planning for a major sporting final or the first cold snap of the winter, there can be multiple factors affecting what our customers buy. The Blue Yonder solution will learn from previous experience and help us predict this more accurately so we can be confident we have the stock our customers want. This will allow us to produce a much more accurate forecast for our suppliers and logistics partners, but will also result in less wastage and better availability for our customers.’’

Gael Ramaen, Corporate Vice President, Retail, EMEA, Blue Yonder, said: “A better forecast is crucial for retailers, and we are thrilled and proud to support Waitrose with their goals of enhancing customer experience and meeting sustainability goals. This builds on the already successful deployment of Blue Yonder Fulfilment and Warehouse Management solutions used within their organisation.”

Additional Resources:

About the John Lewis Partnership

The John Lewis Partnership owns and operates two of Britain's best-loved retail brands - John Lewis and Waitrose. Started as a radical experiment over a century ago, the Partnership is now the largest employee-owned business in the UK, with over 74,000 employees who are all Partners in the business. The Partnership is purpose-driven, existing to create a fairer and more sustainable future for our Partners, customers, suppliers and communities. Our Purpose not only inspires our principles, drives our decisions and acts as our guide to be a force for good, it steers us to do things differently and better - all in service of creating a happier world for everyone and everything we touch. https://www.johnlewispartnership.co.uk/

About Waitrose

Waitrose & Partners has 331 shops in England, Scotland, Wales and the Channel Islands, including 59 convenience branches, 27 shops at Welcome Break locations, and Waitrose.com - its fast-growing online shopping business, consistently rated highly by independent research. The retailer combines the convenience of a supermarket with the expertise and service of a specialist shop - dedicated to offering quality food that has been responsibly sourced, combined with high standards of customer service. As part of an employee-owned business, all Partners have a say in how the business is run. https://www.waitrose.com/

About Blue Yonder

Blue Yonder is the world leader in digital supply chain transformation. Global retailers, manufacturers and logistics providers leverage Blue Yonder to optimize their supply chains from planning through fulfillment, delivery and returns. Blue Yonder’s AI-embedded, interoperable supply chain solutions are connected end-to-end via a unified platform and data cloud, enabling businesses to collaborate in real time across functions, which supports more agile decision-making, improved customer satisfaction, profitable growth, and more resilient, sustainable supply chains. Blue Yonder - Fulfill your Potential blueyonder.com

“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240620098494/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao26.5.2026 09:00:00 CEST | Press release

Kvvit to lead local development, regulatory activities and commercialization of INBRIJA® in mainland China, Hong Kong and Macao​ Under the agreement, Merz Therapeutics will receive upfront, development and commercial milestone payments, and tiered supply and royalty arrangements, with no manufacturing rights granted to Kvvit​ Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor in mainland China, Hong Kong and Macao.​ Under the agreement, Merz will supply INBRIJA® and retain responsibility for global product quality and key regulatory activities. Kvvit will lead development, regulatory activities and commercializat

Poland’s Poznan University of Technology Unveils IQM Quantum Computer to Drive Research and Education26.5.2026 08:49:00 CEST | Press release

IQM Radiance R1 is the first on-premises quantum computer for the PUT. The university aims to use the system to spearhead quantum education and research while boosting STEM in the country. This is the second operational quantum computer deployed in Poland by IQM. The university recognizes the significant long-term potential of integrating quantum computing, artificial intelligence, and high-performance computing (HPC), and intends to play a key role in shaping this transformation in Europe. Poznan University of Technology (PUT) has launched its first locally installed quantum computer, deployed by IQM Quantum Computers, to advance education and scientific research in the field of quantum technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525424085/en/ The moment Poland switched on IQM's second quantum computer. Minister of Science and Higher Education Dr. Marcin Kulasek, IQM CEO Jan Goetz and CCO Sylwia de Weyde

BearingPoint Introduces Fully Sovereign On-Premise Infrastructure for GenAI and Agentic AI in Europe26.5.2026 08:30:00 CEST | Press release

BearingPoint is expanding its AI portfolio with a fully owned, sovereign on-premise and edge infrastructure designed specifically for generative and agentic AI workloads in highly regulated industries and public administrations in Europe. Building on decades of experience operating its own sovereign cloud, the firm now offers clients both dedicated hardware and token-based access to large language models – fully GDPR-compliant, ISO-certified and, on request, NIS2- and DORA-ready BearingPoint announces the launch of the BearingPoint Fully-Owned Sovereign Infrastructure Stack, an infrastructure platform designed, operated, and managed entirely by BearingPoint for GenAI and agentic AI applications, consistently engineered for European sovereignty, compliance, and security. With its own data center in Graz, the solution enables companies and public institutions to run sensitive AI workloads in fully controlled, EU-based environments – from initial innovation projects to mission-critical sc

Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 08:00:00 CEST | Press release

Study Topline results will be released around the end of Q2 2026 BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Pho

Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release

Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye